Skip to main content
. 2022 Jan 6;11(2):183. doi: 10.3390/cells11020183

Figure 3.

Figure 3

Pharmacological targeting of hypoxia-inducible factor signaling to regulate lung endothelial cell injury and repair. HIF-1 signaling in LECs has been shown to promote (green) LEC injury and repair, while HIF-2 signaling in LECs has been shown to inhibit (red) LEC injury and repair (see Table 1 and main text for references). Upstream of HIF-1 and HIF-2, multiple pharmacological agents have been developed to promote (green) or inhibit (red) the 2 major HIF isoforms. Examples of agents that promote HIF-1 signaling include dimethyloxallyl glycine (DMOG) and deferoxamine (DFO); examples of agents that inhibit HIF-1 signaling include CAY-10585 (Cayman Chemical) and chemotin. Examples of agents that promote HIF-2 signaling include FG-4497 (FibroGen) and M1001; examples of agents that inhibit HIF-2 signaling include MK-6482 (Merck) and PT-2385.